Trial Profile

A Post Marketing Surveillance on Piqray (Alpelisib) in Korea

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary)
Indications Advanced breast cancer; Male breast cancer
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

02 Sep 2022 Status changed from not yet recruiting to recruiting.
15 Jun 2022 Planned initiation date changed from 31 May 2022 to 31 Jul 2022.
19 Apr 2022 Status changed from recruiting to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com